ライフサイエンスコーパス: glaucomatous

1 Hundred and fifty five subjects were glaucomatous: (67 PXG, 42 Primary Open Angle Glaucoma (P

2 sociated with maculopathy and different from glaucomatous acquired pits of the optic nerve, which rep

3 e observed decreased MMP-3 activity in human glaucomatous AH compared to age-matched normotensive con

4 Treatment with glaucomatous AH resulted in significantly increased tran

5 ers evaluated differed significantly between glaucomatous and control eyes (P <= 0.045).

6 ocystoid macular changes was similar between glaucomatous and nonglaucomatous eyes.

7 ults at 1 and 6 months were compared between glaucomatous and nonglaucomatous eyes.

8 ntered VF data from the most recent visit of glaucomatous and nonglaucomatous patients into a "pipeli

9 udy was to determine whether IOP lowering in glaucomatous and ocular hypertensive (OHT) eyes leads to

10 levels of these cytokines were higher in the glaucomatous aqueous, but not significantly so.

11 VT in the prelamina has been associated with glaucomatous axonal death, our results suggest that the

12 Eyes were classified as glaucomatous or non-glaucomatous based on documented stereophotographic evid

13 As the abnormal model is based on glaucomatous behaviour this algorithm has not been valid

14 Eyes were classified as glaucomatous by repeatable abnormal standard automated p

15 s of LRRC8A-E subunits were decreased in HTM glaucomatous cells compared to normotensive HTM cells.

16 Thus, ADRVD specifically indicates the glaucomatous central visual loss.

17 d stereophotographic evidence of progressive glaucomatous change in the appearance of the optic nerve

18 G did not develop represents normal aging or glaucomatous change not detected by conventional methods

19 of RGC alone in the identification of early glaucomatous change.

20 as due to technologic limitations to measure glaucomatous change.

21 ard automated perimetry (SAP) or progressive glaucomatous changes on stereophotographs.

22 and potentially could be used to monitor for glaucomatous changes over time.

23 ssure and plays a neuroprotective role under glaucomatous conditions, while voriconazole, an antifung

24 ned from subjects with POAG (n = 99) and non-glaucomatous controls (n = 76).

25 anges to the ONH rim associated with reduced glaucomatous cupping.

26 Optic disc examination showed severe glaucomatous cupping.

27 es together may improve our understanding of glaucomatous damage and aid in the management of patient

28 ated with a greater likelihood of developing glaucomatous damage approximately 12 years later.

29 chosen a priori and included at least 2 with glaucomatous damage but a sensitivity of >/= 6 dB.

30 as the PSD of the 10-2 VF, will miss central glaucomatous damage confirmed with an objective structur

31 lar measurements for detecting preperimetric glaucomatous damage in a cohort of glaucoma suspects.

32 ay be better able to identify pre-perimetric glaucomatous damage in glaucoma suspects than BMO-MRW.

33 Detecting progression of glaucomatous damage is often challenging.

34 ng deep learning (DL) algorithms to classify glaucomatous damage on fundus photographs have been limi

35 Eyes with preperimetric and perimetric glaucomatous damage were included in the glaucoma group.

36 Forty-eight eyes with progressive glaucomatous damage were included in the preperimetric g

37 findings suggest that C3 protects from early glaucomatous damage, a process that may involve EGFR sig

38 nning of the inferior quadrant suggests that glaucomatous damage, more than uveitic ocular hypertensi

39 eactive (IR) cells were highly vulnerable to glaucomatous damage, whereas choline acetyltransferase (

40 ng results in lower IOP and prevents further glaucomatous damage.

41 he study and represented the entire range of glaucomatous damage.

42 cal role for non-NMDA glutamate receptors in glaucomatous damage.

43 the potential to improve early detection of glaucomatous damage.

44 as sensitive as the actual VF for detecting glaucomatous damage.

45 was carried out in 23 patients with typical glaucomatous defects.

46 ONH prelaminar schisis may be a sign of glaucomatous deformation and reflect ongoing pathophysio

47 ompanied by any detectable clinical signs of glaucomatous deterioration.

48 laucoma, and variability in IOP might herald glaucomatous development or progression.

49 l field (Uv-H) (n = 233), and raised IOP and glaucomatous disc and/or visual field (Uv-G) (n = 88).

50 B-scan, the endoscope helped in detecting a glaucomatous disc in 10 of those eyes; 7 of them had gla

51 inal ganglion cells (RGCs) count in identify glaucomatous disease in myopic preperimetric eyes.

52 d in favor of the defendant, and the type of glaucomatous disease or procedure with the highest amoun

53 These findings may help shed light on the glaucomatous disease process and aid efforts to reduce t

54 uded failure to diagnose or mismanagement of glaucomatous disease, as well as adverse drug effects an

55 g epidemiologic evidence linking myopia with glaucomatous disease, but a myopic optic nerve can pose

56 t improvement of patient knowledge regarding glaucomatous disease, follow-up rates were poor for all

57 se positive referrals with more diagnosis of glaucomatous disease.

58 ng medication regimen than those with milder glaucomatous disease.

59 ng of LC3-II in ONH sections from normal and glaucomatous donor eyes was performed.

60 Human TM cells derived from non-glaucomatous donors and from open-angle glaucoma patient

61 dings suggest the possibility of reversal of glaucomatous dysfunction of retinal ganglion cells and t

62 In the glaucomatous eye, this process becomes impaired.

63 We reviewed a total of 227 glaucomatous eyes (38 enrolled, 189 excluded) during an

64 In glaucomatous eyes (46 eyes), mean IOP at presentation wa

65 Totals of 47 glaucomatous eyes (47 patients; VF mean deviation, -12.7

66 [OR], 0.49; 95% CI, 0.22-1.10) or enucleated glaucomatous eyes (OR, 0.66; 95% CI, 0.15-2.89).

67 002, respectively) and remained unchanged in glaucomatous eyes (P = .400 and P = .700, respectively).

68 eyes vs. 66.1+/-9.1mum and 63.4+/-8.2mum in glaucomatous eyes (P<0.001 for both).

69 -5.3mum in healthy eyes vs. 33.9+/-5.0mum in glaucomatous eyes (P<0.001); thicknesses of all other DN

70 hicknesses were compared between healthy and glaucomatous eyes (t-test) and between glaucomatous eyes

71 Our results in glaucomatous eyes also indicate that ILM macrophage cell

72 in 33 of 125 (26.4%) longitudinally followed glaucomatous eyes and 2 of 33 (6%) same-day control pati

73 ty occurs after surgical reduction of IOP in glaucomatous eyes and may represent a potential biomarke

74 loss was significantly faster in progressing glaucomatous eyes compared with healthy eyes for both ri

75 e density of RPCs was significantly lower in glaucomatous eyes compared with matched-peripapillary re

76 phere with apparently normal visual field in glaucomatous eyes compared with the mean hemispheric val

77 size and density were similar in normal and glaucomatous eyes despite lower flow rate through the la

78 C activity, were significantly attenuated in glaucomatous eyes following a time course that matched t

79 AUROC for discriminating between healthy and glaucomatous eyes for cpCD was higher for ED (0.95) comp

80 potential therapeutic targets for protecting glaucomatous eyes from pressure-induced injuries.

81 average number of RGCs in the healthy group, glaucomatous eyes had an average RGC loss of 28.4%, rang

82 eported excellent compliance but only 56% of glaucomatous eyes had IOPs less than 21 mmHg.

83 Glaucomatous eyes had lower temporal and inferior parafo

84 A total of 112 preperimetric glaucomatous eyes of 92 patients were examined to obtain

85 relationship may need further exploration in glaucomatous eyes prior to its application in clinical s

86 l group, which consisted of 32 contralateral glaucomatous eyes receiving antiglaucoma medications wit

87 The thickness of the SNFL slab was less in glaucomatous eyes than in healthy eyes (P<0.001).

88 lm rupture is bigger and increases faster in glaucomatous eyes than in normal eyes.

89 optic disc photographs of 40 healthy and 48 glaucomatous eyes to a visual field chosen from 4 option

90 Normal and glaucomatous eyes underwent spectral-domain optical cohe

91 at the elevated flow resistance found in the glaucomatous eyes was localized to the same region as th

92 found that the CRVT in glaucoma suspect and glaucomatous eyes was located significantly more nasally

93 /- 3.8 mmHg, median 11.8 mmHg, 7-19 mmHg) in glaucomatous eyes was significantly decreased (p < 0.000

94 CT) RNFL raster scans from 98 healthy and 50 glaucomatous eyes were analyzed.

95 age rim area loss in healthy and progressing glaucomatous eyes were compared using multivariate, nest

96 cpCD for discriminating between healthy and glaucomatous eyes were highest in senile sclerotic eyes

97 Glaucomatous eyes were included if localized RNFL defect

98 scopic optic disc photographs of healthy and glaucomatous eyes were presented to clinicians using the

99 Tissues from glaucomatous eyes were stiffer compared with normal eyes

100 The glaucomatous eyes with ADRVDs exhibited inferior rather

101 Twenty-two glaucomatous eyes with ADRVDs had central VF loss.

102 Glaucomatous eyes with an intraocular pressure (IOP) abo

103 In glaucomatous eyes with both quiescent and active uveitis

104 y and glaucomatous eyes (t-test) and between glaucomatous eyes with early, moderate, and severe disea

105 observations indicate that MPOD is lower in glaucomatous eyes with foveal GCC involvement relative t

106 Glaucomatous eyes with GCC loss involving the foveal zon

107 defects of the LC were frequently visible in glaucomatous eyes with localized RNFL defects.

108 indicators of RNFL defects in preperimetric glaucomatous eyes with normal cpRNFL.

109 A total of 180 healthy eyes and 193 glaucomatous eyes with OCTA and OCT imaging of the macul

110 A total of 62 eyes, comprising 38 glaucomatous eyes with open angle glaucoma and 24 health

111 In glaucomatous eyes with single-hemifield damage, the RBF

112 Glaucomatous eyes with the earliest detectable visual fi

113 ects (44 healthy, 59 glaucoma suspect and 89 glaucomatous eyes) were scanned with SD-OCT.

114 er RNFL around the optic disc of healthy and glaucomatous eyes, and it was used to separate the SNFL

115 ently, senescent cells have been observed in glaucomatous eyes, exposing a potential pathway for alte

116 te the prevalence of visual field defects in glaucomatous eyes, glaucoma suspects, and ocular hyperte

117 In glaucomatous eyes, pars plana vitrectomy with epiretinal

118 In glaucomatous eyes, reduced pupillary responses to high-i

119 ored in the tissue with minimal variation in glaucomatous eyes.

120 redict contrast sensitivity (CS) outcomes in glaucomatous eyes.

121 and prelaminar tissue in living healthy and glaucomatous eyes.

122 ized in the SVC, but not the ICP and DVP, in glaucomatous eyes.

123 rate of visual field progression in treated glaucomatous eyes.

124 epleted from RGC axons in the optic nerve of glaucomatous eyes.

125 PA receptor (CP-AMPAR) expression in RGCs of glaucomatous eyes.

126 that influence cataract surgery outcomes in glaucomatous eyes.

127 c nerve head findings frequently observed in glaucomatous eyes.

128 1.7%) eye bank eyes, and 2 (1.3%) enucleated glaucomatous eyes.

129 d in the perimetrically normal hemisphere of glaucomatous eyes.

130 eyes, 517 eye bank eyes, and 155 enucleated glaucomatous eyes.

131 s has great AUC and correlation with VFMD in glaucomatous eyes.

132 al CDR of 0.45 +/- 0.15 vs. 0.80 +/- 0.16 in glaucomatous eyes.

133 nctional progression in glaucoma suspect and glaucomatous eyes.

134 TIMP4 elevation is a novel finding in glaucomatous eyes.

135 RNFL thickness maps of healthy and glaucomatous eyes.

136 ostic ability in distinguishing control from glaucomatous eyes.

137 efined glaucoma" if either disc demonstrated glaucomatous features, and VF data were combined with op

138 shunt implantation from the surgical and the glaucomatous fellow eyes.

139 central CECD compared with baseline and with glaucomatous fellow eyes.

140 ge angle, glaucomatous optic neuropathy, and glaucomatous field defect), glaucoma suspect, ocular hyp

141 ith pre-existing glaucoma had progression of glaucomatous field defect.

142 ALK, 3 of 71 cases (4.48%) developed de novo glaucomatous field defects, and 1 case with pre-existing

143 al-evoked potentials metrics to discriminate glaucomatous from healthy eyes were compared with global

144 e RNFL thickness parameter in discriminating glaucomatous from healthy eyes with receiver operating c

145 area under the ROC curves for discriminating glaucomatous from healthy eyes with the DL predictions a

146 The AUCs for discriminating glaucomatous from healthy eyes with the DL predictions a

147 ion, it is often not possible to distinguish glaucomatous from nonglaucomatous disease based on a sin

148 greater CCT (576.33 +/- 49.32 mum) than the glaucomatous groups (p = 0.004).

149 ing is contrary to TM stiffening reported in glaucomatous human eyes.

150 ted from the inner wall of SC of healthy and glaucomatous human eyes.

151 A patient was considered glaucomatous if at least 2 of the 3 RNFL or GCIPL scans

152 retinal ganglion cell (RGC) survival during glaucomatous injury in a chronic ocular hypertensive rat

153 PERG amplitudes and rate of RGC loss during glaucomatous injury.

154 This suggests dual glaucomatous insults potentiate profibrotic signaling/ph

155 dual-function mechanism to effectively treat glaucomatous intraocular pressure (IOP) dysregulation.

156 Glaucomatous LC cells possessed significantly higher lev

157 41.01 +/- 3.9, p = 0.02, n = 3) was found in glaucomatous LC cells relative to normal LC cells.

158 suited to measure progression of structural glaucomatous loss.

159 The frequency of TTF increased with stage of glaucomatous loss: 28.3% in eyes with mean deviation (MD

160 his report examines the relationship between glaucomatous macular damage and facial recognition.

161 th good central visual acuity, patients with glaucomatous macular damage exhibit diminished facial re

162 Mild diffuse glaucomatous macular damage, as detected by abnormal top

163 his report examines the relationship between glaucomatous macular damage, assessed using structure-fu

164 V4 antagonist prodrug analogs lowered IOP in glaucomatous mouse eyes and protected retinal neurons fr

165 lso describe the use of OCTA to detect early glaucomatous nerve damage, associated with focal reducti

166 ociated with an increased risk of developing glaucomatous nerve damage.

167 rtant role in diseases and injuries, such as glaucomatous neuro-degeneration and retinal detachment.

168 sed upregulation of proteins associated with glaucomatous neurodegeneration in the retina and optic n

169 nduced inhibition of mTOR robustly prevented glaucomatous neurodegeneration, supporting a damaging ro

170 These events lead to IOP elevation and glaucomatous neurodegeneration.

171 Conversely, 11.9% of the glaucomatous neuropathies were misdiagnosed as neurophth

172 The device discriminated eyes with glaucomatous neuropathy from healthy eyes in a clinicall

173 to both intraocular pressure regulation and glaucomatous neuropathy.

174 = 30 months of follow-up with no evidence of glaucomatous neuropathy.

175 bjects) with a central ODP had glaucoma with glaucomatous neuroretinal rim thinning, RNFL loss, and c

176 pendently evaluated 140 image pairs from 100 glaucomatous/ocular hypertensive patient eyes using a ha

177 ctive dataset of 86 618 images, assessed for glaucomatous ONH features and referable GON (defined as

178 ivity, and specificity for referable GON and glaucomatous ONH features.

179 ithm AUCs ranged between 0.661 and 0.973 for glaucomatous ONH features.

180 tous disc in 10 of those eyes; 7 of them had glaucomatous optic atrophy.

181 differences between CG and the suspects with glaucomatous optic disc appearance (GODA).

182 yes of a control group (CG), patients having glaucomatous optic disc appearance or ocular hypertensio

183 nd the spatial relationship between them and glaucomatous optic disc changes such as neuroretinal rim

184 OMPARED WITH PATIENTS WITHOUT PROGRESSION IN GLAUCOMATOUS OPTIC DISC CHANGES.

185 ophotograph review determined progression of glaucomatous optic disc damage.

186 ircumpapillary capillary density (cpCD) of 4 glaucomatous optic disc phenotypes in 193 eyes of 141 gl

187 and 61 (54.0%) eyes did not have progressive glaucomatous optic nerve changes (followed untreated for

188 ng glaucoma, 52 (46.0%) eyes had progressive glaucomatous optic nerve changes and were classified as

189 traction, optic or scleral pit, or advanced glaucomatous optic nerve changes.

190 of 3 signs: intraocular pressure >21 mm Hg, glaucomatous optic nerve damage, and/or glaucomatous vis

191 east one of the following: darkened choroid, glaucomatous optic nerve damage, or conjunctival hyperem

192 onally CD94 status had no detected effect on glaucomatous optic nerve damage.

193 In order to detect glaucomatous optic nerve damages early on and evaluate t

194 ar pressure and hence to prevent progressive glaucomatous optic nerve head damage.

195 The astrocytes in severely glaucomatous optic nerves also showed simplification of

196 tion, proliferative diabetic retinopathy and glaucomatous optic neuropathies (GONs).

197 etween normal tension glaucoma (NTG) and non-glaucomatous optic neuropathies (NGON).

198 nto 3 groups on the basis of the presence of glaucomatous optic neuropathy (GON) and 24-2 visual fiel

199 In patients with glaucomatous optic neuropathy (GON) and pathologic optic

200 isc photographs of subjects with and without glaucomatous optic neuropathy (GON) followed during the

201 valuation Study (ADAGES) with a diagnosis of glaucomatous optic neuropathy (GON) or ocular hypertensi

202 One hundred eyes from 74 patients with glaucomatous optic neuropathy and a 24-2 VF with mean de

203 urophthalmological conditions that may mimic glaucomatous optic neuropathy and to determine which mos

204 Eyes affected by glaucomatous optic neuropathy at presentation were exclu

205 promise optic nerve head perfusion and cause glaucomatous optic neuropathy by creating transient hypo

206 ucoma was based on clinical examination with glaucomatous optic neuropathy defined by the presence of

207 years, the patient also developed bilateral glaucomatous optic neuropathy despite a well-controlled

208 rom 22 countries who self-registered for the Glaucomatous Optic Neuropathy Evaluation (GONE) Project

209 Eyes with visual field abnormality but not glaucomatous optic neuropathy had a higher tendency to b

210 etinal vascular geometry are associated with glaucomatous optic neuropathy independently of vascular

211 ng IOP elevation of >/= 10 mmHg and incident glaucomatous optic neuropathy over the first 2 years com

212 Patients with OHT or glaucomatous optic neuropathy were recruited, and photop

213 a had open iridocorneal angles and displayed glaucomatous optic neuropathy with visual field defects.

214 ere classified as POAG (open drainage angle, glaucomatous optic neuropathy, and glaucomatous field de

215 and to the chronic development of bilateral glaucomatous optic neuropathy.

216 yes with concomitant epiretinal membrane and glaucomatous optic neuropathy.

217 athic epiretinal membranes, with and without glaucomatous optic neuropathy.

218 lary retinal perfusion, which suggests early glaucomatous optic neuropathy.

219 door allergen exposure in the development of glaucomatous optic neuropathy.

220 nds on the signs of chronic angle damage and glaucomatous optic neuropathy.

221 ons in patients, including those affected by glaucomatous optic neuropathy.

222 glaucoma specialists for the probability of glaucomatous optical neuropathy (GON), and estimates of

223 Eyes were classified as glaucomatous or non-glaucomatous based on documented ste

224 re should be taken while classifying them as glaucomatous or not based solely on these characteristic

225 may be applicable to treatments directed at glaucomatous pathology.

226 es were mixed with tests from 21 consecutive glaucomatous patients (42 eyes with normal tension glauc

227 DA (p = 0.005) concentration was observed in glaucomatous patients as compared with controls.

228 Finally, glaucomatous patients injected with VEGF traps (ranibizu

229 Twenty-six medically controlled glaucomatous patients served as controls (medical group)

230 ping behaviours and techniques may help some glaucomatous patients to adapt to their condition.

231 A secondary analysis, in which glaucomatous patients were divided according to VF mean

232 This study included 213 eyes of 125 glaucomatous patients who were followed for an average o

233 spectively enrolled healthy participants and glaucomatous patients with a wide range of disease stage

234 and prelaminar EDI OCT-derived parameters in glaucomatous patients, we found better results for neura

235 involved to preserve injured RGCs such as in glaucomatous patients.

236 stance from the tissue surface in normal and glaucomatous postmortem human eyes, and 1-um spherical A

237 een stable patients (n = 272) and those with glaucomatous progression (n = 78), as determined by visu

238 y will lead to an enhanced ability to detect glaucomatous progression and will allow for more timely

239 Timely detection of glaucomatous progression is crucial in the delivery of g

240 s with statistically significant evidence of glaucomatous progression on OCT Guided Progression Analy

241 The analysis estimated glaucomatous progression on the basis of data from the U

242 Trend analysis techniques to detect glaucomatous progression typically assume a constant rat

243 show floor effect, and that it may indicate glaucomatous progression when the spatially correspondin

244 are limitations in visual field analysis for glaucomatous progression.

245 evalence of betaPPA affect the likelihood of glaucomatous progression.

246 lobal RNFL thickness over time for detecting glaucomatous progression.

247 as development of repeatable abnormal SAP or glaucomatous progressive optic disc changes.

248 t-functionalized biodegradable thermogels in glaucomatous rabbits.

249 ated with the appearance of tau oligomers in glaucomatous retinas.

250 Screening for glaucomatous RNFL changes in uveitis must be performed d

251 Glaucomatous RNFL thinning is predominantly detected wit

252 output to discriminate eyes with repeatable glaucomatous SAP defects vs eyes with normal fields.

253 a reduced tendency for pore formation in the glaucomatous SC cell--likely accounting for increased ou

254 neurodegeneration, transport-intact areas of glaucomatous SC exhibited larger retinal terminals and a

255 OCT data to train a DL algorithm to quantify glaucomatous structural damage on optic disc photographs

256 A total of 758 normal and 58 glaucomatous subjects underwent complete eye examination

257 (myopic subjects), and 7.6 +/- 4.2 degrees (glaucomatous subjects) (all P > .05).

258 , 46 nonglaucomatous myopic subjects, and 86 glaucomatous subjects.

259 We examined the ultrastructure of the glaucomatous superior colliculus (SC) with three-dimensi

260 he change and rate of change were greater in glaucomatous than normal eyes, and were greater than des

261 Glaucomatous TM cell strains have a lower GRbeta-GRalpha

262 Importantly, glaucomatous TM cells exhibit significantly increased pr

263 ealed dysregulated autophagy in aging and in glaucomatous TM cells.

264 lore a novel molecular mechanism involved in glaucomatous TM damage.

265 vivo demonstration that regeneration of the glaucomatous TM is possible and points toward novel appr

266 and phosphatidylinositol between control and glaucomatous TM showed several species common between th

267 Glaucomatous TM tissue is stiffer than age-matched contr

268 ss markers was observed in human post-mortem glaucomatous TM tissues.

269 ncreased ECM accumulation in mouse and human glaucomatous TM tissues.

270 tion of IOP and increased strain observed in glaucomatous TM.

271 The underlying pathological mechanisms of glaucomatous trabecular meshwork (TM) damage and elevati

272 Objective: To model the process of glaucomatous VF decay over the entire perimetric range f

273 The main outcome measure was prediction of glaucomatous VF deterioration according to trend and eve

274 s should be included in prognostic models of glaucomatous VF deterioration.

275 Glaucoma and glaucomatous VF loss are associated with greater likelih

276 GCC thickness can predict the development of glaucomatous VF loss in glaucoma suspects and preperimet

277 te visual field (VF) progression and rate of glaucomatous VF loss in patients with primary angle-clos

278 rt the concept that the measured behavior of glaucomatous VF loss to perimetric blindness is nonlinea

279 ocal LC defects are strongly associated with glaucomatous VF progression, and eyes with focal LC defe

280 ly tool for determination of the severity of glaucomatous vision deficit, the spatial extent of the d

281 benefit from therapy to prevent progressive glaucomatous vision loss.

282 ociation between medication nonadherence and glaucomatous vision loss.

283 s was glaucoma (12/31, 39%), and the risk of glaucomatous visual acuity loss was 15% at 2 years and 2

284 f this study is to determine if glaucoma and glaucomatous visual field (VF) loss are associated with

285 Importance: Identifying the course of glaucomatous visual field (VF) loss that progresses from

286 atiotemporal boundary detection predictor of glaucomatous visual field (VF) progression (STBound) was

287 SITA uses prior distributions of normal and glaucomatous visual field behaviour to estimate threshol

288 n = 9) did not exhibit faster progression of glaucomatous visual field damage compared to matched gla

289 AG was defined as the development of typical glaucomatous visual field loss combined with matching op

290 Rates of glaucomatous visual field loss did not significantly cha

291 sessed the ability to discriminate eyes with glaucomatous visual field loss from healthy eyes with ar

292 e the ability of the network to discriminate glaucomatous visual field loss from normal eyes.

293 Deterioration in eyes with or at risk of glaucomatous visual field loss was "detected" if >= N(th

294 , severity, and functional impact of central glaucomatous visual field loss.

295 tients with glaucoma with moderate to severe glaucomatous visual field loss.

296 an graders at detecting eyes with repeatable glaucomatous visual field loss.

297 Hg, glaucomatous optic nerve damage, and/or glaucomatous visual field loss.

298 al feature in glaucoma and a risk factor for glaucomatous visual field progression, it may be helpful

299 llowing factors were clearly associated with glaucomatous visual field progression: age, disc hemorrh

300 into 2 groups according to TTF in the first glaucomatous visual field: (1) eyes with TTF, defined as